CN107614532A - 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途 - Google Patents

血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途 Download PDF

Info

Publication number
CN107614532A
CN107614532A CN201680018200.7A CN201680018200A CN107614532A CN 107614532 A CN107614532 A CN 107614532A CN 201680018200 A CN201680018200 A CN 201680018200A CN 107614532 A CN107614532 A CN 107614532A
Authority
CN
China
Prior art keywords
antibody
hae
subject
weeks
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680018200.7A
Other languages
English (en)
Chinese (zh)
Inventor
Y·群
B·阿德尔曼
D·J·塞克斯顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57005262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107614532(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CN107614532A publication Critical patent/CN107614532A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680018200.7A 2015-03-30 2016-03-30 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途 Pending CN107614532A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562140289P 2015-03-30 2015-03-30
US201562140277P 2015-03-30 2015-03-30
US62/140,277 2015-03-30
US62/140,289 2015-03-30
US201562214293P 2015-09-04 2015-09-04
US62/214,293 2015-09-04
PCT/US2016/024921 WO2016160926A1 (en) 2015-03-30 2016-03-30 Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack

Publications (1)

Publication Number Publication Date
CN107614532A true CN107614532A (zh) 2018-01-19

Family

ID=57005262

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680018200.7A Pending CN107614532A (zh) 2015-03-30 2016-03-30 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途

Country Status (14)

Country Link
US (2) US20180298110A1 (enExample)
EP (2) EP3916020A1 (enExample)
JP (3) JP7008920B2 (enExample)
KR (3) KR20250057946A (enExample)
CN (1) CN107614532A (enExample)
AU (2) AU2016243160B2 (enExample)
BR (1) BR112017020864A2 (enExample)
CA (1) CA2979713A1 (enExample)
CO (1) CO2017009404A2 (enExample)
EA (1) EA201792161A1 (enExample)
HK (1) HK1250995A1 (enExample)
IL (2) IL305207A (enExample)
MX (2) MX2017012423A (enExample)
WO (1) WO2016160926A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112770751A (zh) * 2018-02-28 2021-05-07 爱顿制药公司 遗传性血管性水肿的治疗
CN114166924A (zh) * 2021-12-03 2022-03-11 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181419T1 (hr) 2010-01-06 2018-11-16 Dyax Corp. Plazma kalikrein vezni proteini
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
CN106132442B (zh) 2014-01-21 2023-07-14 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2017100679A1 (en) * 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
KR20250030022A (ko) * 2016-09-16 2025-03-05 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커
WO2019028362A1 (en) * 2017-08-04 2019-02-07 Dyax Corp. INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
BR112021003789A2 (pt) * 2018-08-30 2021-05-18 Dyax Corp. método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085103A2 (en) * 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
CN103635489A (zh) * 2011-01-06 2014-03-12 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
WO2014152232A2 (en) * 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DE69533472T2 (de) 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
PT1941867E (pt) 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
LT2704742T (lt) * 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JP6444315B2 (ja) * 2013-01-20 2018-12-26 ダイアックス コーポレーション ブラジキニン媒介障害の評価および治療
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR20250066486A (ko) * 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
CN106132442B (zh) * 2014-01-21 2023-07-14 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085103A2 (en) * 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
CN103635489A (zh) * 2011-01-06 2014-03-12 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
WO2014152232A2 (en) * 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUNG CHYUNG ET AL: "A phase 1 study investigating DX-2930 in healthy subjects", 《ANN ALLERGY ASTHMA IMMUNOL》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112770751A (zh) * 2018-02-28 2021-05-07 爱顿制药公司 遗传性血管性水肿的治疗
CN114166924A (zh) * 2021-12-03 2022-03-11 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途

Also Published As

Publication number Publication date
KR20250057946A (ko) 2025-04-29
EP3916020A1 (en) 2021-12-01
IL254292B1 (en) 2025-09-01
AU2022203180B2 (en) 2025-09-11
KR20170135885A (ko) 2017-12-08
KR102799778B1 (ko) 2025-04-28
CA2979713A1 (en) 2016-10-06
IL305207A (en) 2023-10-01
EP3286226A1 (en) 2018-02-28
HK1250995A1 (zh) 2019-01-18
JP2023130442A (ja) 2023-09-20
WO2016160926A1 (en) 2016-10-06
EA201792161A1 (ru) 2018-04-30
JP7309836B2 (ja) 2023-07-18
IL254292A0 (en) 2017-10-31
MX2017012423A (es) 2018-01-26
NZ774543A (en) 2024-04-26
JP7008920B2 (ja) 2022-01-25
BR112017020864A2 (en) 2018-07-10
KR102607829B1 (ko) 2023-12-01
US20220169749A1 (en) 2022-06-02
JP2022037131A (ja) 2022-03-08
MX2023010206A (es) 2023-09-11
US20180298110A1 (en) 2018-10-18
AU2016243160B2 (en) 2022-02-24
EP3286226A4 (en) 2018-12-05
NZ735659A (en) 2023-08-25
KR20230164767A (ko) 2023-12-04
CO2017009404A2 (es) 2018-03-09
AU2022203180A1 (en) 2022-06-02
JP2018514510A (ja) 2018-06-07
AU2016243160A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
US12384854B2 (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
JP7309836B2 (ja) 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
US20230104754A1 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2021146160A1 (en) Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
HK40064044A (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
NZ735659B2 (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210611

Address after: 1-1, sidingmu, xiudaocho, Central District, Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: Daix GmbH

TA01 Transfer of patent application right